David Hoffman documents a frantic and eventually stillborn effort by the Department of Defense to develop new agents for treating patients with pandemic influenza ("Going Viral," January 31st).
D. James Baker Former Administrator National Oceanic and Atmospheric Administration Washington, D.C. David Hoffman documents a frantic and eventually stillborn effort by the Department of Defense to develop new agents for treating patients with pandemic influenza ("Going Viral," January 31st).
David S. Fedson, M.D. Former Professor of Medicine School of Medicine at the University of Virginia Sergy Haut, France David Hoffman documents a frantic and eventually stillborn effort by the Department of Defense to develop new agents for treating patients with pandemic influenza ("Going Viral," January 31st).
Care HPS was designed to easily and quickly develop new agent-based models.
Thus, for many years, numerous attempts have been made to develop new agents capable of preventing and/or treating periodontitis (Park et al. 2005).
Current strategies are directed to prolong the effect of intravitreal anti-VEGF agents, to develop new agents with different mechanisms, and to combine agents with synergetic effects.
Antibiotic resistance is a rapidly evolving health concern that requires a sustained effort to understand mechanisms of resistance and to develop new agents that overcome those mechanisms.
It is essential to understand the molecular level response of crosslinked cellulose chain segments upon deformation, in order to develop new agents which convey high durable-press (DP) rating to cellulose fibers with minimal strength loss.
Consequently, efforts are needed to evaluate and develop new agents to combat this ongoing health crisis.
Basic research is also fundamental to develop new agents for patients.
As a result, there is a clear unmet clinical need to develop new agents.
